期刊文献+
共找到207篇文章
< 1 2 11 >
每页显示 20 50 100
Role of non-steroidal anti-inflammatory drugs on intestinal permeability and nonalcoholic fatty liver disease 被引量:12
1
作者 erika utzeri paolo usai 《World Journal of Gastroenterology》 SCIE CAS 2017年第22期3954-3963,共10页
The use of non-steroidal anti-inflammatory drugs(NSAIDs) is widespread worldwide thanks to their analgesic, anti-inflammatory and antipyretic effects. However, even more attention is placed upon the recurrence of dige... The use of non-steroidal anti-inflammatory drugs(NSAIDs) is widespread worldwide thanks to their analgesic, anti-inflammatory and antipyretic effects. However, even more attention is placed upon the recurrence of digestive system complications in the course of their use. Recent data suggests that the complications of the lower gastro-intestinal tract may be as frequent and severe as those of the upper tract. NSAIDs enteropathy is due to enterohepatic recycling of the drugs resulting in a prolonged and repeated exposure of the intestinal mucosa to the compound and its metabolites. Thus leading to so-called topical effects, which, in turn, lead to an impairment of the intestinal barrier. This process determines bacterial translocation and toxic substances of intestinal origin in the portal circulation, leading to an endotoxaemia. This condition could determine a liver inflammatory response and might promote the development of nonalcoholic steatohepatitis, mostly in patients with risk factors such as obesity, metabolic syndrome and a high fat diet, which may induce a small intestinal bacterial overgrowth and dysbiosis. This alteration of gut microbiota may contribute to nonalcoholic fatty liver disease and its related disorders in two ways: firstly causing a malfunction of the tight junctions that play a critical role in the increase of intestinal permeability, and then secondly leading to the development of insulin resistance, body weight gain, lipogenesis, fibrogenesis and hepatic oxidative stress. 展开更多
关键词 Non-steroidal anti-inflammatory drugs Intestinal barrier Intestinal permeability Non-steroidal anti-inflammatory drugs - enteropathy Nonalcoholic fatty liver disease Nonalcoholic steatohepatitis MICROBIOTA Metabolic syndrome Proton pump inhibitors ENDOTOXAEMIA
下载PDF
Protocol Driven Approach to Optimize the Absorption of Physically Incompatible Drugs with Enteral Formulations
2
作者 William Ruspantini Movses Hovsepian +2 位作者 Asha Bhalla Andrew Chu Edwina Rich 《Journal of Pharmacy and Pharmacology》 2015年第10期443-450,共8页
The purpose of this study was to determine the feasibility of a protocol-driven approach to optimize the absorption of drugs physically incompatible with enteral nutrition in critical care patients on continuous tube ... The purpose of this study was to determine the feasibility of a protocol-driven approach to optimize the absorption of drugs physically incompatible with enteral nutrition in critical care patients on continuous tube feeds during 6 quarterly review periods. A hospital-based interdisciplinary protocol was approved in which physically incompatible drugs could be converted from the IV (intravenous) or oral formulation to an enteral formulation and administered during a "no tube-feed" interval. Eligible patients included those receiving continuous TF (tube feed formulas) and enterally administered medications for at least 2 days while receiving a physically incompatible target drug from the protocol. The primary outcome was the percentage of physically incompatible target drugs successfully converted to the appropriate enteral formulation and administration time. The secondary outcomes were the cost savings of all enteral target drugs converted during each quarter based on a 7 day review and the total cost savings of each target drug converted during the entire study. The primary outcome of successful drug conversions to the appropriate enteral administration was 100% for 5 of the 6 quarters and 81 percent for one quarter. The secondary outcome of cost savings of all enteral drug conversions averaged $975 per quarter. Also, the cost savings of each of the enteral target drug conversions for the entire study was between $3,376 for the most costly drug and $26 for least costly drug. The study shows that an interdisciplinary protocol with "no tube-feed" intervals is a feasible and cost effective method to successfully optimize the absorption of physically incompatible drugs with enteral formulas during continuous tube feedings. 展开更多
关键词 Protocol-driven drugS incompatIBLE enteral nutrition.
下载PDF
Synthesis of (2S,4S)-2-Substituted-3- (3-Sulfanylpropanoyl)-6- Oxohexahydropyrimidine-4-Carboxylic Acids as Potential Antihypertensive Drugs
3
作者 Andrei Ershov Dmitry Nasledov +1 位作者 Igor Lagoda Valery Shamanin 《Journal of Materials Science and Chemical Engineering》 2015年第6期7-12,共6页
Proceeding from natural amino acid L-asparagine and commercially available aldehydes a stereoselective synthesis was developed of (2S,4S)-2-alkyl(aryl)-3-(3-sulfanylpropanoyl)-6-oxohexahy- dropyrimidine-4-carboxylic a... Proceeding from natural amino acid L-asparagine and commercially available aldehydes a stereoselective synthesis was developed of (2S,4S)-2-alkyl(aryl)-3-(3-sulfanylpropanoyl)-6-oxohexahy- dropyrimidine-4-carboxylic acids, potential antihypertensive drugs, inhibitors of the angiotensin converting enzyme. 展开更多
关键词 Synthesis of (2S 4S)-2-Substituted-3- (3-Sulfanylpropanoyl)-6- Oxohexahydropyrimidine-4-Carboxylic ACIDS AS POTENTIAL ANTIHYPERTENSIVE drugS
下载PDF
Association of KRAS Gene and microRNA-124-3p in Sporadic Colorectal Tumours
4
作者 Ozkan Bagci 《Journal of Biosciences and Medicines》 2024年第1期150-161,共12页
Aim: To reveal the exonic and 3’UTR sequences of KRAS, TP53, APC, BRAF, PIK3CA genes in sporadic colorectal tumors and to investigate the clinical relevance of 3’UTR variations in miRNA profiles. Methods: In the stu... Aim: To reveal the exonic and 3’UTR sequences of KRAS, TP53, APC, BRAF, PIK3CA genes in sporadic colorectal tumors and to investigate the clinical relevance of 3’UTR variations in miRNA profiles. Methods: In the study, the exonic and 3’UTR sequences of five genes in 12 sporadic colorectal tumors were extracted by next generation sequencing. In tumors with variation in the 3’UTR region, the changes caused by the variation in the miRNA binding profile were detected. The expression profile of these miRNAs in colorectal and other solid tumors compared to normal tissue was determined. Pathway analysis was performed to determine which signaling pathways miRNAs affect. Results: Case-10 in our study was wild type KRAS and received cetuximab treatment and developed drug resistance. In this case, it was concluded that the expression of KRAS increased and tumorigenesis progressed due to miRNAs that do not bind to this region due to variations in the 3’UTR region. Among these miRNAs, hsa-miR-124-3p was found to have decreased expression in colorectal tumors and to be associated with the ECM-receptor interaction pathway. Conclusion: Variations in the 3’UTR regions of genes critical in the process of carsinogenesis are associated with drug resistance and the process of tumorigenesis. 展开更多
关键词 Colorectal Tumours drug Resistance Personalised Medicine microRNA-124-3p
下载PDF
高效液相色谱-离子阱质谱法测定人血浆中的头孢拉定和青霉素G 被引量:7
5
作者 李晓东 尹利辉 冯玉飞 《分析测试学报》 CAS CSCD 北大核心 2004年第z1期8-11,共4页
  目前,β-内酰胺类抗生素在临床抗感染药物中占有十分突出的地位[1],但在近年来的药品不良反应报告中,抗生素类药物引起的不良反应也占据了很高的比例,其中有我国生活环境影响、感染性疾病多的客观因素,但病人用药盲目性大、医生用...   目前,β-内酰胺类抗生素在临床抗感染药物中占有十分突出的地位[1],但在近年来的药品不良反应报告中,抗生素类药物引起的不良反应也占据了很高的比例,其中有我国生活环境影响、感染性疾病多的客观因素,但病人用药盲目性大、医生用药随意性多的问题也普遍存在.…… 展开更多
关键词 HPLC - Ion trap mass spectrometry Penicillin G CEFRADINE drug concentration in plasma
下载PDF
药液酸碱度对阿莫西林-克拉维酸与其他药物配伍产生沉淀的影响 被引量:10
6
作者 方忠宏 宋新余 周湘兰 《中国新药与临床杂志》 CAS CSCD 北大核心 2002年第6期374-376,共3页
目的 :探讨在配伍用药产生沉淀与药物溶液 pH的关系。方法 :将阿莫西林 克拉维酸参考医嘱处方 ,以氯化钠注射液按比例稀释 ,然后与环丙沙星、庆大霉素适当混合 ,观察出现的沉淀情况 ;再加必要的试剂 ,观察其变化。并按药典规定的方法... 目的 :探讨在配伍用药产生沉淀与药物溶液 pH的关系。方法 :将阿莫西林 克拉维酸参考医嘱处方 ,以氯化钠注射液按比例稀释 ,然后与环丙沙星、庆大霉素适当混合 ,观察出现的沉淀情况 ;再加必要的试剂 ,观察其变化。并按药典规定的方法测定有关溶液 pH值 ,通过比较 ,确定 pH值与其发生沉淀的关系。结果 :阿莫西林 克拉维酸与pH较低的药物环丙沙星、庆大霉素配伍时出现沉淀 ,滴加氢氧化钠试液使溶液 pH升高后 ,溶液变澄清。结论 :pH降低是阿莫西林 克拉维酸与环丙沙星、庆大霉素配伍产生沉淀的原因 ,为保证临床用药的安全性及有效性 ,应注意不同药物溶液的 pH差异 ,避免因药物溶液 展开更多
关键词 药液酸碱度 药物配伍 阿莫西林 克拉维酸 氢离子浓度 庆大霉素 环丙沙星
下载PDF
哌替啶及丙帕他莫与β-内酰胺类药物配伍实验 被引量:2
7
作者 杨舜娟 林淑瑜 +1 位作者 潘丹婷 甘惠贞 《医药导报》 CAS 北大核心 2014年第1期108-110,共3页
目的探讨微量输液泵内哌替啶及丙帕他莫与β-内酰胺类药物在双通道输液管中出现白色结晶的原因。方法通过对相同药物配伍进行重复和模拟实验来寻找配伍禁忌的原因。结果输液泵中哌替啶在双通道中遇到β-内酰胺类药物会产生白色浑浊;注... 目的探讨微量输液泵内哌替啶及丙帕他莫与β-内酰胺类药物在双通道输液管中出现白色结晶的原因。方法通过对相同药物配伍进行重复和模拟实验来寻找配伍禁忌的原因。结果输液泵中哌替啶在双通道中遇到β-内酰胺类药物会产生白色浑浊;注射用丙帕他莫不稳定,分解产物导致输液的pH降低,配伍3 h后输液的pH为3.34,溶液遇到β-内酰胺类药物等不耐酸性的药物开始发生配伍变化,在24 h内输液的pH从5.37逐渐降至1.87,配伍液由无色澄清变为白色结晶。结论输液泵中注射用丙帕他莫不宜长时间慢速滴注,应单独使用输液管路。含有哌替啶的输液泵液体不宜使用多通道管路输液器与β-内酰胺类药物同时进行输注,应单独使用输液管路。 展开更多
关键词 哌替啶 丙帕他莫 Β-内酰胺类药物 配伍禁忌
下载PDF
川芎汤与冠心Ⅱ号吸收入人血清中阿魏酸的血药浓度-时间曲线 被引量:6
8
作者 任平 黄熙 +3 位作者 陈可冀 张莉 王骊丽 马晓昌 《心脏杂志》 CAS 2000年第4期253-254,共2页
目的 :探讨方剂配伍对吸收入体内血药浓度及其药物动力学参数的影响。方法 :用已建立的 HPL C法 [1 ] ,测定健康自愿者一次口服川芎汤 (1g· kg- 1 )、冠心 号汤 (6 g/kg,其中川芎为 1g/kg)后血清中阿魏酸 (FA)的血药浓度 -时间曲... 目的 :探讨方剂配伍对吸收入体内血药浓度及其药物动力学参数的影响。方法 :用已建立的 HPL C法 [1 ] ,测定健康自愿者一次口服川芎汤 (1g· kg- 1 )、冠心 号汤 (6 g/kg,其中川芎为 1g/kg)后血清中阿魏酸 (FA)的血药浓度 -时间曲线。结果 :均表现为双峰现象 ;川芎汤和冠心 号在健康人血清中 FA的血药浓度时间曲线下面积(AU C)分别为 15 735± 70 6 4和 15 886± 80 6 2 μg· L- 1· m in- 1 ;健康人血清中川芎复方来源的 FA血药浓度最高和最低定量值之间表现出 3~ 8倍的差异。结论 :在冠心 号中川芎配伍芍药、红花和丹参等并不影响体内 FA的血药浓度及其生物利用度。 展开更多
关键词 方剂 血药浓度 药物配伍禁忌 川芎 阿魏酸
下载PDF
反相高效液相色谱法-二极管阵列检测器考察盐酸氨溴索注射液与注射用头孢唑肟钠配伍稳定性 被引量:1
9
作者 郑芳 朱雪松 +1 位作者 刘菁 李春雷 《中国医药》 2010年第8期735-737,共3页
目的考察盐酸氨溴索注射液与注射用头孢唑肟钠分别在5%葡萄糖注射液和0.9%氯化钠注射液中的配伍稳定性。方法在室温[(22±1)℃]下,采用反相高效液相色谱法-二极管阵列检测器测定盐酸氨溴索与头孢唑肟钠配伍后0~6h内的含量变... 目的考察盐酸氨溴索注射液与注射用头孢唑肟钠分别在5%葡萄糖注射液和0.9%氯化钠注射液中的配伍稳定性。方法在室温[(22±1)℃]下,采用反相高效液相色谱法-二极管阵列检测器测定盐酸氨溴索与头孢唑肟钠配伍后0~6h内的含量变化,并观察配伍液的外观及pH。结果6h内混合液外观、pH无明显变化,盐酸氨溴索在5%葡萄糖注射液其含量在0~6h内变化为:100%、99.5%、99.2%、98.8%、99%、98.2%、98.6%;在0.9%氯化钠注射液中0~6h内变化为:100%、99.1%、99.5%、99.4%、100.7%、100.3%、100.1%。头孢唑肟在5%葡萄糖注射液中其含量为100%、100.2%、100.5%、99.8%、98.3%、99.3%、99%;在0.9%氯化钠注射液其含量为100%、99.5%、99.7%、99.3%、99.8%、98.9%、98.6%,表明该配伍试验基本稳定。结论在室温[(22±1)℃]条件下,盐酸氨溴索注射液与注射用头孢唑肟钠在5%葡萄糖注射液和0.9%氯化钠注射液中6h内配伍稳定。 展开更多
关键词 色谱法 高压液相 氨溴索 头孢唑肟 药物配伍禁忌 药物稳定性
下载PDF
环氧酶-2选择性抑制剂的再认识 被引量:2
10
作者 费允云 张奉春 《临床药物治疗杂志》 2008年第4期27-30,共4页
非甾体抗炎药(nonsteroidal anti-inflammatory drugs,NSAIDs)是一类具有抗炎与镇痛作用的药物,可以改善风湿性疾病的炎性症状并可缓解疼痛,是世界范围内使用最广泛的一类处方药。NSAIDs的作用机制是通过抑制环氧酶(cyclooxygena... 非甾体抗炎药(nonsteroidal anti-inflammatory drugs,NSAIDs)是一类具有抗炎与镇痛作用的药物,可以改善风湿性疾病的炎性症状并可缓解疼痛,是世界范围内使用最广泛的一类处方药。NSAIDs的作用机制是通过抑制环氧酶(cyclooxygenanse,COX)的活性进而阻断花生四烯酸转化为前列腺素、前列环素和血栓素A,(TXA,)而发挥其药理作用。但使用NSAIDs的过程中,尤其是长期、大量服用时可出现副作用,其中最常见的副作用是对胃肠道的损害。 展开更多
关键词 环氧酶-2 选择性抑制剂 非甾体抗炎药 NSAIDS drugS 风湿性疾病 花生四烯酸 镇痛作用
下载PDF
住院病儿使用利奈唑胺致5-羟色胺毒性相关的用药禁忌情况调查 被引量:1
11
作者 陈璐琳 杨巨飞 +1 位作者 方罗 叶伟峰 《安徽医药》 CAS 2020年第9期1905-1908,共4页
目的调查使用利奈唑胺治疗的住院病儿存在的5-羟色胺毒性相关的用药禁忌情况。方法通过查阅中英文数据库和药品说明书,整理与利奈唑胺存在5-羟色胺毒性相关的用药禁忌的药品,回顾性收集浙江大学医学院附属儿童医院2018年1月1日至12月31... 目的调查使用利奈唑胺治疗的住院病儿存在的5-羟色胺毒性相关的用药禁忌情况。方法通过查阅中英文数据库和药品说明书,整理与利奈唑胺存在5-羟色胺毒性相关的用药禁忌的药品,回顾性收集浙江大学医学院附属儿童医院2018年1月1日至12月31日使用利奈唑胺的住院病儿的住院信息和用药信息,对用药禁忌情况进行统计分析。结果住院药房共24种药品与利奈唑胺存在5-羟色胺毒性相关的用药禁忌。全院有1 510例次使用利奈唑胺,用药禁忌发生率为24.6%。利奈唑胺在血液科的使用率和用药禁忌发生率最高,分别为42.5%和32.9%;重症监护室(ICU)次之,分别为21.0%和25.6%;其中合用例次较多的禁忌药品有氨溴特罗口服溶液、愈酚甲麻那敏糖浆、枸橼酸芬太尼注射液。结论利奈唑胺在住院病儿临床应用广泛,与氨溴特罗口服溶液、愈酚甲麻那敏糖浆、枸橼酸芬太尼注射液等多种存在5-羟色胺毒性相关的禁忌药物合用的发生率较高,这需要引起医务工作者,特别是血液科和ICU医生的足够重视。 展开更多
关键词 处方不当 药物配伍禁忌 药物相互作用 药物副反应报告系统 血清素 利奈唑胺 单胺氧化酶抑制剂 5-羟色胺毒性
下载PDF
Effect of Nano - Titanium Dioxide with Different Antibiotics against Methicillin-Resistant Staphylococcus Aureus 被引量:5
12
作者 Aashis S. Roy Ameena Parveen +1 位作者 Anil R. Koppalkar M. V. N. Ambika Prasad 《Journal of Biomaterials and Nanobiotechnology》 2010年第1期37-41,共5页
The different investigation has been carried out on the biological activities of titanium dioxide nanoparticle but the effect of this nano product on the antibacterial activity of different antibiotics has not been ye... The different investigation has been carried out on the biological activities of titanium dioxide nanoparticle but the effect of this nano product on the antibacterial activity of different antibiotics has not been yet demonstrated. In this study the nano size TiO2 is synthesized using citric acid and alpha dextrose and the enhancement effect of TiO2 nanoparticle on the antibacterial activity of different antibiotics was evaluated against Methicillin-resistant Staphylococcus aureus (MRSA). During the present study, different concentrations of nano-scale TiO2 were tested to find out the best concentration that can have the most effective antibacterial property against the MRSA culture. Disk diffusion method was used to determine the antibacterial activity of these antibiotics in the absence and presence of sub inhibitory concentration of TiO2 nano particle. A clinical isolate of MRSA, isolated from Intensive Care Unit (ICU) was used as test strain. In the presence of sub-inhibitory concentration of TiO2 nanoparticle (20 μg/disc) the antibacterial activities of all antibiotics have been increased against test strain with minimum 2 mm to maximum 10mm. The highest increase in inhibitory zone for MRSA was observed against pencillin G and amikacin (each 10 mm). Conversely, in case of nalidixic acid, TiO2 nanoparticle showed a Synergic effect on the antibacterial activity of this antibiotic against test strain. These results signify that the TiO2 nanoparticle potentate the antimicrobial action of beta lactums, cephalosporins, aminoglycosides, glycopeptides, macrolids and lincosamides, tetracycline a possible utilization of nano compound in combination effect against MRSA. 展开更多
关键词 NANO - Titanium OXIDE S. AUREUS drug Resistance ANTIBACTERIAL Activity
下载PDF
NAG-1抗肿瘤的机制及其表达调控
13
作者 王静 王春晖 《华西医学》 CAS 2008年第4期926-927,共2页
关键词 抗肿瘤机制 TGF-Β超家族 表达调控 转化生长因子-Β 非甾体类消炎药 促凋亡 活化基因 drug
下载PDF
EP4 agonist alleviates indomethacin-induced gastric lesions and promotes chronic gastric ulcer healing 被引量:1
14
作者 Wha Bin Im Yariv Donde Larry A Wheeler 《World Journal of Gastroenterology》 SCIE CAS CSCD 2009年第41期5149-5156,共8页
AIM: To investigate EP4-selective agonist effect on indomethacin-induced gastric lesions and on the spontaneous healing of chronic gastric ulcers. METHODS: In a mouse model of gastric bleeding with high dose of indo... AIM: To investigate EP4-selective agonist effect on indomethacin-induced gastric lesions and on the spontaneous healing of chronic gastric ulcers. METHODS: In a mouse model of gastric bleeding with high dose of indomethacin (20 mg/kg), an EP4-selective agonist was administered orally. Stomach lesions and gastric mucous regeneration were monitored. In a mouse model of chronic gastric ulcer induced by acetic acid, EP4 agonist effect on the healing of chronic gastric ulcer was evaluated in the presence or absence of low dose indomethadn (3 mg/kg). In cultured human gastric mucous cells, EP4 agonist effect on indomethacin- induced apoptosis was assessed by flow cytometry. RESULTS: The EP4-selective agonist reduced high dose indomethacin-induced acute hemorrhagic damage and promoted mucous epithelial regeneration. Low-dose indomethacin aggravated ulcer bleeding and inflammation, and delayed the healing of the established chronic gastric ulcer. The EP4 agonist, when applied locally, not only offset indomethacin-induced gastric bleeding and inflammation, but also accelerated ulcer healing. In the absence of indomethacin, the EP4 agonist even accelerated chronic gastric ulcer healing and suppressed inflammatory cell infiltration in the granulation tissue. In vitro, the EP4 agonist protected human gastric mucous cells from indomethacin-induced apoptosis.CONCLUSION: EP4-selective agonist may prevent indomethacin-induced gastric lesions and promote healing of existing and i ulcers, via promoting mucous epithelial cells. proliferation and survival of mucous epithelial cells. 展开更多
关键词 Prostaglandin E2 Non-steroidal anti-inflam- matory drugs Gastric bleeding Gastric ulcer EP4- subtype receptor
下载PDF
基于网络药理学和分子对接技术探讨十九畏药对“郁金-丁香”抗肝纤维化作用机制 被引量:1
15
作者 汪居安 王居义 +5 位作者 蔡叶 李幸蓉 吴凌 伊艳敏 檀啸 王继洲 《安徽医药》 CAS 2023年第6期1083-1087,F0002,I0001,共7页
目的 通过网络药理学和分子对接技术探讨郁金-丁香药对抗肝纤维化的作用机制。方法 于2022年1月8日检索中药系统药理学数据平台(TCMSP)获取郁金和丁香的有效活性成分及相关靶点并进行筛选和预测;肝纤维化相关靶点的数据通过NCBI基因数据... 目的 通过网络药理学和分子对接技术探讨郁金-丁香药对抗肝纤维化的作用机制。方法 于2022年1月8日检索中药系统药理学数据平台(TCMSP)获取郁金和丁香的有效活性成分及相关靶点并进行筛选和预测;肝纤维化相关靶点的数据通过NCBI基因数据、OMIM数据库和Genecards数据库获取;运用软件Venny 2.1绘制药物-疾病靶点韦恩图,得到药物抗肝纤维化的作用靶点;运用Cytoscape 3.8.2软件构建药物-活性成分-靶点相互作用网络并分析其拓扑结构;运用String数据库构建蛋白质相互作用(PPI)网络图;利用David和Metascape数据库对关键靶点分别进行基因本体(GO)和京都基因与基因组百科全书(KEGG)富集分析;利用PubChem和RCSBPDB数据库对关键成分和靶点进行分子对接。结果 筛选得到郁金-丁香药活性成分44个,对应作用靶点200个,肝纤维化候选靶点3 951个,药物与疾病交集靶点155个。药物-活性成分-靶点网络和PPI网络分析显示槲皮素、山柰酚、柚皮素、β-谷甾醇等是药对治疗肝纤维化的关键成分,蛋白激酶B1(AKT1)、白细胞介素(IL)-6、IL-1β、牛胱天蛋白酶3(CASP3)等为治疗的核心靶点。155个潜在靶点经GO富集至1 889条生物学过程、44条细胞组分表达和94个分子功能相关的过程中。KEGG通路分析显示与133条通路有关,涉及癌症信号通路、乙型肝炎信号通路、TNF信号通路、Toll样受体信号通路等。分子对接表明关键成分与核心靶点结合良好。结论 从网络药理学角度阐明了郁金-丁香药多成分、多靶点、多途径的整体调节特点,初步揭示了其抗肝纤维化的作用机制,为后续研究提供思路与依据。 展开更多
关键词 肝纤维化 十九畏 郁金 丁香 网络药理学 分子对接 蛋白质相互作用图谱
下载PDF
澳大利亚John Murtagh全科病案研究(四十八)--一位骨关节病和最近发生高血压病人的费解症状
16
作者 John Murtagh 《中国全科医学》 CAS CSCD 北大核心 2013年第19期2198-2200,共3页
John Murtagh,澳大利亚Monash大学全科医学系兼职教授和Melbourne大学的全科医学专家。1966年毕业于Monash大学,1986年担任《Australian Family Physician》杂志主编,1988年获得医学博士学位,1993年被Monash大学聘为教授。1995年,鉴于... John Murtagh,澳大利亚Monash大学全科医学系兼职教授和Melbourne大学的全科医学专家。1966年毕业于Monash大学,1986年担任《Australian Family Physician》杂志主编,1988年获得医学博士学位,1993年被Monash大学聘为教授。1995年,鉴于他在医学教育、研究和著作方面的卓越贡献,被授予澳大利亚勋章,他的著作《Murtagh's General Practice》被奉为澳大利亚全科医生的"圣经"。其著作在中国也产生了巨大的影响。《Murtagh'sGeneral Practice》中译本已在2010年岁末出版发行。"澳大利亚John Murtagh全科病案研究"自2008年开始在《中国全科医学》杂志连续刊登以来,受到了广大中国全科医生的关注和好评。Murtagh教授每一个娓娓道来的病案都是他毕生宝贵工作经验的精华,是为《中国全科医学》杂志专门撰写,是中国全科医生前进的导航和指引。本期JohnMurtagh教授给我们讲述了一位骨关节病和最近发生高血压病人的费解症状。澳大利亚Monash大学杨辉教授对本文进行了翻译点评,以飨我国读者。在此衷心感谢Murtagh教授和担任本栏目翻译点评工作的杨辉教授对中国全科医学发展给予的大力支持和帮助! 展开更多
关键词 药物相互作用 药物配伍禁忌 共病现象
下载PDF
HPLC法测定盐酸法舒地尔注射液与葡萄糖注射液配伍液中的5-羟甲基糠醛 被引量:2
17
作者 程永科 李锐 陈祖利 《现代医药卫生》 2016年第9期1317-1319,共3页
目的测定盐酸法舒地尔注射液与葡萄糖注射液配伍液中的5-羟甲基糠醛(5-HMF)。方法采用高效液相色谱法(HPLC),色谱柱:Wetch C18柱(150.0 mm×4.6 mm×5.0μm),流动相:0.05 mol/L磷酸二氢铵溶液-乙腈(89∶11),流速:1.0... 目的测定盐酸法舒地尔注射液与葡萄糖注射液配伍液中的5-羟甲基糠醛(5-HMF)。方法采用高效液相色谱法(HPLC),色谱柱:Wetch C18柱(150.0 mm×4.6 mm×5.0μm),流动相:0.05 mol/L磷酸二氢铵溶液-乙腈(89∶11),流速:1.0 m L/min,检测波长:284 nm,柱温:25℃,进样量:20μL。结果 5-HMF在1.45-2.61μg/m L内线性关系良好(r=0.999 8);平均回收率为97.4%(RSD=1.1%)。结论采用HPLC测定盐酸法舒地尔注射液与葡萄糖注射液配伍液中的5-HMF方法简便,准确可靠。 展开更多
关键词 色谱法 高压液相 盐酸 葡萄糖 注射剂 药物配伍禁忌 糠醛/类似物和衍生物
下载PDF
Mechanism of "Epimedium-Cistanche deserticola" in the treatment of breast cancer with bone metastasis
18
作者 Yun Mao Xue-Lei Chu +4 位作者 Peng Xue Lin-Lu Li Yi-Xin Su Sheng-Qi He Shi-Jie Zhu 《Journal of Hainan Medical University》 2020年第4期19-25,共7页
Objective:"Epimedium - Cistanche deserticola" is a kind of kidney tonifying drug commonly used in the treatment of breast cancer bone metastasis, which has good clinical effect, but the pharmacological mecha... Objective:"Epimedium - Cistanche deserticola" is a kind of kidney tonifying drug commonly used in the treatment of breast cancer bone metastasis, which has good clinical effect, but the pharmacological mechanism has not been fully clarified. Methods: In this study, the network pharmacology and bioinformatics technology were used to explore the mechanism of "Epimedium - Cistanche deserticola" in the treatment of breast cancer bone metastasis. TCMSP, TCM database@Taiwan and TCMID databases were used to screen the main effective components of the drug. Swiss Target Prediction and STITCH databases were used to search the potential target of action of Epimedium and Cistanche deserticola. Genecards, OMIN and Drugbank databases were used to search the cause of bone metastasis of breast cancer. The target of action of the drug and the disease gene were mapped for GO and KEGG signal pathway analysis, A visualized network of "drug - component - target - signaling pathway" was constructed by using the software of Cytoscape 3.6.0, and the core genes were screened out. Results: The study found that there are 30 main effective components of Epimedium and Cistanche deserticola, and 544 genes are involved in the potential therapeutic targets, among which 101 genes are potential targets of Epimedium and Cistanche deserticola in the treatment of breast cancer bone metastasis. Through the analysis of GO and KEGG pathways, we found that the mechanisms involved in antitumor, osteoblast differentiation, osteoclast apoptosis and regulation of bone microenvironment, such as apoptosis, osteoclast differentiation, PI3K-Akt, HIF-1 signaling pathway, T cell receptor signaling pathway, etc. TP53, VEGFA, AKT1, EGFR, SRC, CCND1, MAPK3, ESR1 may be the key genes in the treatment of breast cancer bone metastasis. Conclusion: In this study, the network of "drug - component - target- signaling pathway" was constructed through network pharmacology, and it was found that the mechanism of "Epimedium - Cistanche deserticola" in the treatment of breast cancer bone metastasis involves multiple targets and pathways, which is conducive to guiding clinical medication. 展开更多
关键词 Bone METASTASIS of BREAST cancer Network PHARMACOLOGY "Epimedium - CISTANCHE deserticola" drug pair MECHANISM of action
下载PDF
肾素-血管紧张素-醛固酮系统的肾脏保护效应
19
作者 余国膺 《中国心脏起搏与心电生理杂志》 2006年第4期284-284,共1页
关键词 肾素-血管紧张素-醛固酮系统 末期肾脏疾病 保护效应 LANCET ALLHAT Effect review drugS RENAL ACE-I
下载PDF
美国FDA就环氧化酶-2抑制剂和非甾体类抗炎药物作出重要决定
20
作者 黄琳 《上海医药》 CAS 2005年第5期230-230,共1页
关键词 非甾体类抗炎药物 环氧化酶-2抑制剂 美国FDA 环氧化酶-2(COX-2) 美国食品和药品管理局 胃肠道不良反应 药品安全使用 2005年 drugs 非选择性 药物相关 消费者 非处方 说明书 类药物 可能性 心血管
下载PDF
上一页 1 2 11 下一页 到第
使用帮助 返回顶部